Rallybio Corporation

RLYB

$16.77

-1.00%

2026-09-03 12:23:47 EDT-$0.17

Healthcare

Biotechnology

NASDAQ

Active Trading

Rallybio Corporation is a clinical-stage biotechnology firm dedicated to discovering and bringing to market transformative therapies for individuals facing severe and uncommon ...

Price Action of RLYB

$16.77

-1.00%-$0.17

High—

Low—

52W High-4.6%

Rel. vol—

Interval

Range2.2h

Volume—SMA5SMA10

—

Rallybio Corporation, headquartered in New Haven, Connecticut, is a clinical-stage biotechnology company founded in 2018 by former Alexion Pharmaceuticals executives, including current CEO Stephen Uden. The company is dedicated to bringing transformative therapies to patients with severe and uncommon illnesses, with a focus on rare diseases. Its most advanced candidate, ...Rallybio Corporation, headquartered in New Haven, Connecticut, is a clinical-stage biotechnology company founded in 2018 by former Alexion Pharmaceuticals executives, including current CEO Stephen Uden. The company is dedicated to bringing transformative therapies to patients with severe and uncommon illnesses, with a focus on rare diseases. Its most advanced candidate, RLYB212, a monoclonal anti-HPA-1a antibody, is in Phase II clinical trials for preventing FNAIT, a condition that can cause bleeding in fetuses and newborns. Another candidate, RLYB211, targets the same condition. The pipeline also includes RLYB114, a preclinical pegylated C5-targeted Affibody for ophthalmic diseases, and RLYB116, a C5 inhibitor that has completed Phase 1 trials for complement dysregulation disorders. Additionally, RLYB332, a preclinical antibody, is being developed for severe anemia with ineffective erythropoiesis and iron overload. The company has formed strategic collaborations with AbCellera for antibody discovery, Exscientia for small molecule development, and Johnson & Johnson to deliver therapies for FNAIT. Financially, with a market cap of approximately $86.9 million and no debt, Rallybio maintains a strong cash position of about $16.29 per share. The company employs 14 full-time staff, though it recently announced a 40% workforce reduction. Despite its early stage, Rallybio is committed to scientific innovation and has a robust R&D focus, with research and development expenses representing 13.35 times its revenue. Its long-term vision is to transform the lives of millions affected by rare diseases, leveraging the expertise of its seasoned team.ExpandCollapse

Founded

2018

Employees

CEO

Stephen Uden

Full Name

Rallybio Corporation

Sector

Healthcare

Industry

Biotechnology

ROE

68.56%

Market Cap

$0.09B

Current Ratio

27.26

WACC

5.46%

ROIC

27.92%

Contact Information

https://www.rallybio.com

203 859 3820

234 Church Street, New Haven, CT 06510

Key Metrics of RLYB

Snapshot

Latest / TTM · 6 periods

Market Cap

$89.00M

ROCE

-25.1%

EV / EBITDA

-0.12x

+23.2% YoY

FCF Yield

29.4%

+125.9% YoY

Cash Conversion Cycle

-39.0d

Current Ratio

27.26

Quick take

TTM —

No major risk flags in selected headline metrics.

Financial Highlights of RLYB

Profitability trend

Latest / TTM · 6 periods

Gross Margin

-1107.6%

Net Margin

7051.2%

P/E Ratio

2.13x

n/a

Debt / Equity

0.00

n/a

Current Ratio

27.26

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Calendar of RLYB

Upcoming

Sep 30, 2026In 26 days
Q3 FY2026 · Estimated results
Est. EPS $-1.44 · Revenue $0.00 · 1 analysts
Dec 30, 2026
Q4 FY2026 · Estimated results
Est. EPS $-1.60 · Revenue $0.00 · 1 analysts
Dec 31, 2026
FY2026 · Estimated annual results
Est. EPS $-5.52 · Revenue $80000.00 · 1 analysts
Dec 31, 2027
FY2027 · Estimated annual results
Est. EPS $-11.52 · Revenue $87.90M · 1 analysts

Recent history

Aug 6, 2026
Q2 FY2026 · Results reported
EPS $7.53 · Revenue $0.00
View filing
May 13, 2026
Q1 FY2026 · Results reported
EPS $-1.46 · Revenue $212000.00
View filing
Mar 16, 2026
FY2025 · Annual results
EPS $-1.59 · Revenue $858000.00
View filing
Nov 6, 2025
Q3 FY2025 · Results reported
EPS $2.84 · Revenue $212000.00
View filing
Aug 7, 2025
Q2 FY2025 · Results reported
EPS $-1.76 · Revenue $212000.00
View filing
May 8, 2025
Q1 FY2025 · Results reported
EPS $-1.68 · Revenue $212000.00
View filing

Financial Statements of RLYB

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	$858000	+34.9%	-100.0%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	$-9.0M	+84.5%	+627.5%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	+89.3%	+101.5%	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	-3270.9%	+65.6%	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	-1046.4%	+88.5%	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	$-29.8M	+39.5%	+670.9%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	-3474.7%	+55.2%	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	0.3%	+21.6%	-100.0%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	14.50x	+33.5%	+111.0%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	$62.3M	-8.6%	+80.0%

Actual vs Estimate

A Dec 31Q Jun 30

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	-1.59 vs -1.80	+11.7%	7.53 vs -1.28	+688.3%
Revenue Surprise	$858000 vs $700000	+22.6%	—	—

Insider Transactions of RLYB

Acquisitions (A)

Since May 12, 2026

Disposals (D)

Since May 12, 2026

Monthly shares of acquisitions/disposals with close price trend (shared daily price source)

Insider Trading Snapshot

Date	Executive	Title	Security	Side	Shares	Price
Jul 6, 2026	Boudreau Helen M	director	Common Stock	A	3,562	$2.38
Jul 6, 2026	Boudreau Helen M	director	Option (Right to Buy)	D	3,562	$2.38
May 19, 2026	ADAR1 Capital Management, LLC	10 percent owner	Common Stock	A	200	$13.80
May 19, 2026	ADAR1 Capital Management, LLC	10 percent owner	Common Stock	A	10,000	$13.98
May 18, 2026	ADAR1 Capital Management, LLC	10 percent owner	Common Stock	A	6,009	$13.98

Leadership Team of RLYB

3 executives

Name	Title	Compensation	Gender	Year Born	Status
Stephen Uden	Co-Founder, President, Chief Executive Officer & Director	USD 857,980	—	1958	Active
Jonathan I. Lieber	Chief Financial Officer & Treasurer	USD 645,488	Male	1970	Active
Martin W. MacKay	Co-Founder & Chairman	USD 290,000	—	1956	Active

Recent News of RLYB

GuruFocus7/21/2026Neutral

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 21, 2026

PRNewsWire7/21/2026Neutral

Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

GuruFocus6/9/2026Neutral

Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 9, 2026

PRNewsWire6/9/2026Neutral

Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws

GuruFocus6/2/2026Neutral

Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick and Foti, LLC (âKSFâ) are investigating the proposed merger of

Historical Employee Count of RLYB

Current

Change

-44.00%

Minimum

Maximum

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	14	10-K	Mar 16, 2026	View
Dec 31, 2024	25	10-K	Mar 13, 2025	View
Dec 31, 2023	43	10-K	Mar 12, 2024	View
Dec 31, 2022	41	10-K	Mar 6, 2023	View
Dec 31, 2021	35	10-K	Mar 15, 2022	View

Related stocksBiotechnology

Browse all US stocks →

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer

Rallybio Corporation